𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A new ditriazine inhibitor of NF-κB modulates chronic inflammation and angiogenesis

✍ Scribed by Inmaculada Rioja; Carmen M. Terencio; Amalia Ubeda; Ricardo Riguera; José M. Quintela; José M. Alcaraz

Publisher
Springer-Verlag
Year
2002
Tongue
English
Weight
152 KB
Volume
365
Category
Article
ISSN
0028-1298

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Amelioration of acute inflammation by sy
Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-κB activation
✍ Paola di Meglio; Angela Ianaro; Sankar Ghosh 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 598 KB

## Abstract ## Objective We used an experimental model of inflammation in mice, carrageenan‐induced paw edema, to study the antiinflammatory effects of the NEMO‐binding domain (NBD) peptide, which blocks activation of the inducible transcription factor NF‐κB. ## Methods Paw edema was induced by

A new NF-κB inhibitor based on the amino
A new NF-κB inhibitor based on the amino-epoxyquinol core of DHMEQ
✍ Tsuyoshi Saitoh; Chika Shimada; Masatoshi Takeiri; Mitsuhiro Shiino; Shigeru Ohb 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 899 KB

The amino-epoxyquinols 6a and 6b were synthesized as soluble derivatives of an NF-κB inhibitor DHMEQ (1). In spite of the opposite configuration from 1, 6b rather than 6a affected the deactivation of NF-κB, based on NO secretion and MALDI-TOF MS analysis. It was indicated that 6b inhibited the activ

A novel NF-κB inhibitor DHMEQ selectivel
A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo
✍ Mariko Watanabe; Md. Zahidunnabi Dewan; Takamitu Okamura; Masataka Sasaki; Kinji 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 453 KB

Multiple myeloma (MM) is a fatal lymphoid malignancy that is incurable with conventional modalities of chemotherapy. Strong and constitutive activation of nuclear factor kappa B (NF-kappaB) is a common characteristic of MM cells. In our study we successfully target NF-kappaB with a novel NF-kappaB i

Simvastatin, 3-hydroxy-3-methylglutaryl
Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-κB ligand through modulation of NF-κB pathway
✍ Kwang Seok Ahn; Gautam Sethi; Madan M. Chaturvedi; Bharat B. Aggarwal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 631 KB

## Abstract Simvastatin, an inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase, is a cholesterol‐lowering drug that may play a role in bone metabolism through a mechanism that is not fully understood. Recently, receptor activator of NF‐κB ligand (RANKL), a member of the TNF superfamily, h